Clinical Features and Seroepidemiology of Anti-HDV Antibody in Patients With Chronic Hepatitis B Virus Infection in Iran: A Meta-Analysis

被引:17
作者
Amini, Neda [2 ]
Alavian, Seyed Moayed [1 ]
Kabir, Ali [3 ,4 ]
Hosseini, Seyed Yaser Saiedi [1 ]
Aalaei-Andabili, Seyed Hossein [1 ]
机构
[1] Baqiyatallah Univ Med Sci, Baqiyatallah Res Ctr Gastroenterol & Liver Dis, Tehran, Iran
[2] Univ Tehran Med Sci, Students Sci Res Ctr, Tehran, Iran
[3] Univ Tehran Med Sci, Ctr Educ Res Med Sci, Tehran, Iran
[4] Shahid Beheshti Univ Med Sci, Dept Epidemiol, Tehran, Iran
关键词
Hepatitis D; Review; Meta-Analysis; Iran; Prevalence; Epidemiology; HBSAG POSITIVE PATIENTS; DELTA-VIRUS; PHYLOGENETIC ANALYSIS; PREVALENCE; EPIDEMIOLOGY; IMPACT; CIRRHOSIS; PROVINCE; SEROPREVALENCE; TEHRAN;
D O I
10.5812/kowsar.1735143X.805
中图分类号
R57 [消化系及腹部疾病];
学科分类号
摘要
Context: Hepatitis delta virus (HDV) leads to the most severe form of chronic viral hepatitis. Objectives: To determine the prevalence of HDV and create pooled estimations of possible risk factors, a systematic review was conducted to collect all epidemiological studies on HDV among chronic hepatitis B patients in Iran. Data Sources: In this systematic review, databases such as PubMed, Embase, ISI, Google scholar, and Iranian databases (Maglran, lranmedex, and SID) were searched. Study Selection: Studies that clearly stated information about the number of HBsAg positive patients infected with HDV were selected. Data Extraction: The name of the city, the author's name, year of study, HDV detection method, sample size, HBsAg positive frequency, mean age, total prevalence of HDV, and risk factors were extracted. Results: The pooled HDV prevalence was 7.8% (95% CI:5.89 - 9.71). In the survey-data analysis, HDV prevalence was 6.61%. HDV prevalence was 30.47% (95% CI: 9.76 to 51.19), 14.4% (95% CI: 7.72 to 21.07), and 4.94% (95% CI: 3.73 to 6.15) in cirrhotic, chronic-hepatitis, and inactive-carrier patients, respectively. Pooled ORs were calculated for several factors common to Iranian HBsAg-positive patients, including history of blood transfusion [OR: 1.1 (95% CI: 0.40 to 2.98)], intravenous drug abuse [OR: 1.6 (95% CI: 0.78 to 3.21)], previous hemodialysis [OR: 1.72 (95% Cl: 0.79 to 3.76)], and HBeAg-positive status [OR:1.26 (95% CI: 0.66 to 2.4)]. Conclusions: The prevalence of HDV is less common in Iran than in endemic regions such as Italy and Turkey; however, it is a severe form of hepatitis in HBsAg-positive patients. The most probable route of HDV transmission is hematologic, which suggests the importance of blood screening for HDV, especially in groups with numerous blood transfusions. Copyright (C) 2011 Kowsar M. P. Co. All rights reserved.
引用
收藏
页码:960 / 967
页数:8
相关论文
共 59 条
  • [1] Hepatitis D: Scenario in the Asia-Pacific region
    Abbas, Zaigham
    Jafri, Wasim
    Raza, Sajjad
    [J]. WORLD JOURNAL OF GASTROENTEROLOGY, 2010, 16 (05) : 554 - 562
  • [2] Prevalence of hepatitis delta antibody-among HBsAg carriers in Saudi Arabia
    Al Traif, I
    Ali, A
    Dafalla, M
    Al Tamimi, W
    Qassem, L
    [J]. ANNALS OF SAUDI MEDICINE, 2004, 24 (05) : 343 - 344
  • [3] Alavian S., 2005, Hepatitis Monthly, V5, P137
  • [4] Hepatitis C infection in hemodialysis patients in Iran: A systematic review
    Alavian, Seyed-Moayed
    Kabir, Ali
    Ahmadi, Amir Bahrami
    Lankarani, Kamran Bagheri
    Shahbabaie, Mohammad Ali
    Ahmadzad-Asl, Masoud
    [J]. HEMODIALYSIS INTERNATIONAL, 2010, 14 (03) : 253 - 262
  • [5] Alavian SM, 2008, HEPAT MON, V8, P245
  • [6] Alavian SM, 2004, GOVARESH, V9, P169
  • [7] Seroprevalence of Hepatitis D Virus and its Risk Factors in the West of Iran
    Alizadeh, Amir Houshang Mohammad
    Ranjbar, Mitra
    Tehrani, Ali Shabahang Saber
    Keramat, Fariba
    Mamani, Moggan
    Rezazadeh, Mehdi
    Aini, Peyman
    Khalilian, Alireza
    Majlesi, Amir
    Hajilooi, Mehrdad
    [J]. JOURNAL OF MICROBIOLOGY IMMUNOLOGY AND INFECTION, 2010, 43 (06) : 519 - 523
  • [8] AMINI S, 1993, J TROP MED HYG, V96, P277
  • [9] Amini S, 2007, HAKIM RES J, V9, P7
  • [10] Ataei B, 2009, CLIN MICROBIOL INFEC, V15, pS586